Related to India Orders First Compulsory License for Bayer's Nexavar Cancer Drug to Natco

• Patent Reform Battle Pits Biotech against High-Tech
  The former fears increased infringement due to lower damages under the Patent Reform Act of 2009 making its way through Congress.
  
• Intellectual Property at Crossroads
  The convergence of the patent system with the regulatory system presents complicated issues.
  
• Potential Effects of Pending Biologics Legislation on the Patent Application Process
  While patent reform may get bumped to a later Congress, a resolution to biosimilars law may get passed as part of a healthcare reform bill.
  
• Bridges that Indian Biosimilar Makers Must Cross to Prosper in International Markets
  Firms will need to tackle affordability, assets, approvability, acceptability, and availability.
  
• Market Exclusivity—Paramount in Evaluating Target Companies
  The main related factors are relevant facts, freedom to operate, IP, third-party agreements, and regulatory exclusivity.
  
• Federal Circuit Holds that Methods of Optimizing Drug Efficacy Are Patentable
  Pending U.S. Supreme Court decision could further transform the standard for patentability of medical diagnostic claims.
  
• Opening Up the Lines of Communication at the Patent Office
  Changes to the count system, which tracks examiners’ workflow, grant them one more hour to conduct interviews.
  
• Part 1—The U.S. International Trade Commission and Intellectual Property
  Advantages of going to the ITC over U.S. courts include speedy resolutions and remedies that prohibit infringers from the entire U.S. market.
  
• Part 2—Tips for Biotech/Pharma Complainants and Respondents When Going to the ITC
  Going to the ITC provides needed tools like foreign discovery that are not available in a district court.
  
• Court Confirms “Separate” Written Description Requirement
  Decision draws more scrutiny to the validity of broad claims and impacts the decision on when to file an application.
  
• FTC Challenges to Patent Settlements Entering a New Stage
  Recent rulings suggest that the FTC will need to act against these settlements within the framework of existing case law.
  
• Asia-Pacific’s March toward a New Drug Development Paradigm
  Increasing investment, embracing new R&D models, and aligning regulatory agencies are key to the region’s success.
  
• Opinion: Watson, Come Here … You're Needed at the PTO
  Without a transformation of the information technology supporting patent examiners, patent reform would be like rearranging the deck chairs on the Titanic.
  
• Patent Reform Likely to Benefit Industry Giants More Than Start-Ups
  Points of concern in the America Invents Act include provisions for first-to-file and inequitable conduct.
  
• Stanford v. Roche Could Place Tech Transfer on Shaky Ground
  If Supreme Court doesn’t overturn previous decision, patent ownership may become tough to verify and impede licensing.
  
• IP Rules for Synthetic Bio Generate More Questions Than Answers
  Among unresolved issues are gene patentability, patent protection vs. open access, and the effect of patent reform.